These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34530900)

  • 1. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.
    Herviou L; Ovejero S; Izard F; Karmous-Gadacha O; Gourzones C; Bellanger C; De Smedt E; Ma A; Vincent L; Cartron G; Jin J; De Bruyne E; Grimaud C; Julien E; Moreaux J
    Clin Epigenetics; 2021 Sep; 13(1):174. PubMed ID: 34530900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors.
    Milite C; Feoli A; Viviano M; Rescigno D; Mai A; Castellano S; Sbardella G
    ChemMedChem; 2016 Aug; 11(16):1680-5. PubMed ID: 27411844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells.
    Kukita A; Sone K; Kaneko S; Kawakami E; Oki S; Kojima M; Wada M; Toyohara Y; Takahashi Y; Inoue F; Tanimoto S; Taguchi A; Fukuda T; Miyamoto Y; Tanikawa M; Mori-Uchino M; Tsuruga T; Iriyama T; Matsumoto Y; Nagasaka K; Wada-Hiraike O; Oda K; Hamamoto R; Osuga Y
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
    Wada M; Kukita A; Sone K; Hamamoto R; Kaneko S; Komatsu M; Takahashi Y; Inoue F; Kojima M; Honjoh H; Taguchi A; Kashiyama T; Miyamoto Y; Tanikawa M; Tsuruga T; Mori-Uchino M; Wada-Hiraike O; Osuga Y; Fujii T
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
    Veschi V; Liu Z; Voss TC; Ozbun L; Gryder B; Yan C; Hu Y; Ma A; Jin J; Mazur SJ; Lam N; Souza BK; Giannini G; Hager GL; Arrowsmith CH; Khan J; Appella E; Thiele CJ
    Cancer Cell; 2017 Jan; 31(1):50-63. PubMed ID: 28073004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SETD8 inhibition targets cancer cells with increased rates of ribosome biogenesis.
    Murga M; Lopez-Pernas G; Soliva R; Fueyo-Marcos E; Amor C; Faustino I; Serna M; Serrano AG; Díaz L; Martínez S; Blanco-Aparicio C; Antón ME; Seashore-Ludlow B; Pastor J; Jafari R; Lafarga M; Llorca O; Orozco M; Fernández-Capetillo O
    Cell Death Dis; 2024 Sep; 15(9):694. PubMed ID: 39341827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SETD8/PR-Set7 Methyltransferase Functions as a Barrier to Prevent Senescence-Associated Metabolic Remodeling.
    Tanaka H; Takebayashi SI; Sakamoto A; Igata T; Nakatsu Y; Saitoh N; Hino S; Nakao M
    Cell Rep; 2017 Feb; 18(9):2148-2161. PubMed ID: 28249161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone lysine methyltransferase SETD8 regulates angiogenesis through HES-1 in human umbilical vein endothelial cells.
    Choi DK; Kim YK; Park SW; Lee H; Lee S; Kim SA; Kim SJ; Lee J; Kim W; Min SH; Yu JH
    Sci Rep; 2020 Jul; 10(1):12089. PubMed ID: 32694555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship studies of SETD8 inhibitors.
    Ma A; Yu W; Xiong Y; Butler KV; Brown PJ; Jin J
    Medchemcomm; 2014 Dec; 5(12):1892-1898. PubMed ID: 25554733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PPARγ-SETD8 axis constitutes an epigenetic, p53-independent checkpoint on p21-mediated cellular senescence.
    Shih CT; Chang YF; Chen YT; Ma CP; Chen HW; Yang CC; Lu JC; Tsai YS; Chen HC; Tan BC
    Aging Cell; 2017 Aug; 16(4):797-813. PubMed ID: 28514051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles for the methyltransferase SETD8 in DNA damage repair.
    Xu L; Zhang L; Sun J; Hu X; Kalvakolanu DV; Ren H; Guo B
    Clin Epigenetics; 2022 Mar; 14(1):34. PubMed ID: 35246238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of lysine methyltransferase SETD8 in human diseases.
    Milite C; Feoli A; Viviano M; Rescigno D; Cianciulli A; Balzano AL; Mai A; Castellano S; Sbardella G
    Clin Epigenetics; 2016; 8():102. PubMed ID: 27688818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC.
    Li X; Liu Z; Xia C; Yan K; Fang Z; Fan Y
    Cancer Lett; 2022 Feb; 527():150-163. PubMed ID: 34942305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Determinants of Erythropoiesis: Role of the Histone Methyltransferase SetD8 in Promoting Erythroid Cell Maturation and Survival.
    DeVilbiss AW; Sanalkumar R; Hall BD; Katsumura KR; de Andrade IF; Bresnick EH
    Mol Cell Biol; 2015 Jun; 35(12):2073-87. PubMed ID: 25855754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
    Ma A; Yu W; Li F; Bleich RM; Herold JM; Butler KV; Norris JL; Korboukh V; Tripathy A; Janzen WP; Arrowsmith CH; Frye SV; Vedadi M; Brown PJ; Jin J
    J Med Chem; 2014 Aug; 57(15):6822-33. PubMed ID: 25032507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone methyltransferase Setd8 acts in concert with c-Myc and is required to maintain skin.
    Driskell I; Oda H; Blanco S; Nascimento E; Humphreys P; Frye M
    EMBO J; 2012 Feb; 31(3):616-29. PubMed ID: 22117221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SETD8 inhibits apoptosis and ferroptosis of Ewing's sarcoma through YBX1/RAC3 axis.
    Chen H; Hu J; Xiong X; Chen H; Liao Q; Lin B; Chen Y; Peng Y; Li Y; Cheng D; Li Z
    Cell Death Dis; 2024 Jul; 15(7):494. PubMed ID: 38987564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer.
    Liu M; Qin Y; Hu Q; Liu W; Ji S; Xu W; Fan G; Ye Z; Zhang Z; Xu X; Yu X; Zhuo Q
    Cancer Lett; 2021 Feb; 499():265-278. PubMed ID: 33232789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.
    Takawa M; Cho HS; Hayami S; Toyokawa G; Kogure M; Yamane Y; Iwai Y; Maejima K; Ueda K; Masuda A; Dohmae N; Field HI; Tsunoda T; Kobayashi T; Akasu T; Sugiyama M; Ohnuma S; Atomi Y; Ponder BA; Nakamura Y; Hamamoto R
    Cancer Res; 2012 Jul; 72(13):3217-27. PubMed ID: 22556262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule inhibitors of SETD8 with cellular activity.
    Blum G; Ibáñez G; Rao X; Shum D; Radu C; Djaballah H; Rice JC; Luo M
    ACS Chem Biol; 2014 Nov; 9(11):2471-8. PubMed ID: 25137013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.